JPRN-UMIN000009126已完成未知
Evaluation of efficacy of dose escalation strategy for treatment with sorafenib for hepatocellular carcinoma. - Evaluation of efficacy of dose escalation strategy for treatment with sorafenib for hepatocellular carcinoma.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Brain metastases. 2. Bleeding tendency. 3. Advanced ascites. 4. Hepatic encephalopathy (II or more). 5. Jaundice (serum bilirubin value of 3.0 mg/dL or more). 6. Serum AST or ALT value of more than 200 IU/L. 7. Hemoglobin blood value of less than 8.0 g/dL. 8. Neutrophil count of less than 1000 /microL. 9. Platelet count of less than 50000 /microL. 10. Difficult to control hypertension. 11. During dialysis. 12. Patients who are pregnant, suspected to be pregnant or breastfeeding. 13. Patient with drug allergy. 14. Patient uses other anticancer drugs. 15. Patients who are considered not to be eligible by the investigators.
研究者
相似试验
进行中（未招募）
1 期
A study to assess the efficacy and tolerance of AF-219 in patients with long term coughEUCTR2015-000474-35-GBAfferent Pharmaceuticals, Inc.59
招募中
2 期
Evaluation of efficacy and safety of dose-escalating lenalidomide and dexamethasone (Ld) therapy and adapted therapy adding elotuzumab with insufficient efficacy by Ld therapy in newly diagnosed, transplant ineligible multiple myeloma patients (DELAYED study)Multiple MyelomaJPRN-UMIN000036377Gifu university hospital33
已完成
不适用
Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaireOveractive BladderJPRN-UMIN000004894Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan500
终止
2 期
To identify the effective dose(s) of RT234 (vardenafil inhalation powder) to acutely improve pulmonary vascular haemodynamics in study participants with Pulmonary Arterial Hypertension (PAH).Cardiovascular - Other cardiovascular diseasesPulmonary Arterial HypertensionACTRN12619001178134Respira Therapeutics Australia Pty Ltd14
已完成
1 期
Phase 1 study of BAY 3283142 in Japanese healthy male participantsChronic kidney diseaseJPRN-jRCT2071230002Myoishi Masafumi36